Document is current
Any future updates will be listed below
-
Authors
Wang, Ting-Ching
Dollahon, Christina R. https://orcid.org/0000-0003-2628-5342
Mishra, Sneha
Patel, Hailee
Abolghasemzade, Samere
Singh, Ishita
Thomazy, Vilmos
Rosen, Daniel G.
Sandulache, Vlad C. https://orcid.org/0000-0002-9205-385X
Chakraborty, Saptarshi
Lele, Tanmay P. https://orcid.org/0000-0001-8574-1251
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (U01 CA225566)
Cancer Prevention and Research Institute of Texas (RR200043)
U.S. Department of Veterans Affairs (1I01CX002776)
- License Information
-
More Information
Article History
Received: 20 July 2024
Accepted: 24 November 2024
First Online: 2 December 2024
Competing interests
: VCS is a consultant and equity holder for Femtovox Inc (unrelated to current work). TCW, CRD, SM, HP, SA, IS, VT, DGR, SC, and TPL declare no competing interests.
